Team "Psychiatry"
Anne Giersch
Anne Giersch
email: giersch[at]unistra.fr
Anne Giersch is a research director at INSERM. The team aims to understand the pathophysiology of schizophrenia in order to develop new therapies. Schizophrenia is currently only defined by clinical symptoms. Studying cognitive disorders is aimed at establishing links between the disease and neurobiology. In 2016, the team published a study showing that schizophrenic patients have greater sensitivity to pain than the scientific community has believed for years. EURIDOL enables the team to treat pain in schizophrenia and collaborate on their applied research. This partnership also helps raise questions about other risk factors such as cannabis, known to relieve chronic pain. Dr. Laurence Lalanne especially focused on these questions through research on addiction in Anne Giersch's laboratory.
Team "Addiction"
Laurence Lalanne & Emmanuel Darcq
Laurence Lalanne & Emmanuel Darcq
email: llalanne[at]unistra.fr & edarcq[at]unistra.fr
The Addictions team, is based at the CRBS (Centre de Recherche Biomédicale de Strasbourg) in the INSERM STEP Unit, and studies the mechanisms of addictive disorders to opioids, alcohol and cannabis in relation to psychiatric comorbidities. The team is translational, with clinical research led by Laurence Lalanne and pre-clinical research led by Emmanuel Darcq. The clinical research team, focuses on the problem of addictive disorders in relation to psycho-social and epigenetic factors. The pre-clinical team goals are to elucidate the neurobiological mechanisms, and more specifically the brain circuits involved in relapse and abstinence. Pre clinical team is also studying the role of G protein-coupled receptors (GPCRs) in addictive disorders.
Research areas: Addiction ; Depression ; Opioids ; Cocaine ; cannabis.
Techniques: Clinical techniques and Preclinical ; Behavioural tests ; Optogenetic ; Fiber photometry ; Spatial transcriptomic.